"New Approach To Melanoma Treatment Identified" - Marilynn Larkin
Drugs that induce a self-inflicted cell-death process called ferroptosis could be used to target de-differentiated melanoma cells, thereby increasing the efficacy of both targeted and immune therapies, researchers suggest. The team also found that cell subtypes that de-differentiated - meaning they reverted back to a less mature cell - were sensitive to ferroptosis. Philip Friedlander, MD, PhD, assistant professor of medicine, hematology and medical oncology and director of the melanoma medical oncology program at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai said, "The work presented is very intriguing and hypothesis generating. Further investigation is needed to determine in the clinical setting with stage IV melanoma patients if the induction of ferroptosis improves the efficacy of immunotherapy and of anti-BRAF targeted therapy.”
- Philip Friedlander, MD, PhD, Assistant Professor, Medicine, Hematology, Medical Oncology, Dermatology, Director, The Melanoma Medical Oncology Program, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai